Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis

Primary Care Diabetes

Volumn 6, Issue 2, 2012, Pages 109-121

  Palmer, A J ^a,b   Tucker, D M D ^a,b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b Critical Health Research Pty Ltd   (Australia)

Author keywords

Cost effectiveness; Diabetes; Economic; High risk; Lifestyle change; Metformin; Outcomes; Prevention

Indexed keywords

GLUCOSE; METFORMIN;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; ECONOMIC ASPECT; FEMALE; HEALTH STATUS; HIDDEN MARKOV MODEL; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; INTENSIVE LIFESTYLE CHANGE; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE PAYMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; THIRD PARTY PAYER; TREATMENT OUTCOME;

AGED; AUSTRALIA; COST SAVINGS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MARKOV CHAINS; METFORMIN; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861331845     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2011.10.006     Document Type: Article

References (49)

1. The Burden of Disease and Injury in Australia 2003 Australian Institute of Health and Welfare
2. The Economic Costs of Obesity 2006 Access Economics
3. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 6865 2001 782 787
4. D.W. Dunstan, P.Z. Zimmet, T.A. Welborn, C. de, A.J. Cameron, R.A. Sicree, T. Dwyer, S. Colagiuri, D. Jolley, M. Knuiman, R. Atkins, and J.E. Shaw The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study Diabetes Care 25 5 2002 829 834
5. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, and D.M. Nathan Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346 6 2002 393 403
6. J. Tuomilehto, J. Lindstrom, J.G. Eriksson, T.T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Laakso, A. Louheranta, M. Rastas, V. Salminen, and M. Uusitupa Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N. Engl. J. Med. 344 18 2001 1343 1350
7. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 9323 2002 2072 2077
8. L. Perreault, S.E. Kahn, C.A. Christophi, W.C. Knowler, and R.F. Hamman Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program Diabetes Care 32 9 2009 1583 1588
9. A. Ramachandran, C. Snehalatha, S. Mary, B. Mukesh, A.D. Bhaskar, and V. Vijay The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) Diabetologia 49 2 2006 289 297 10.1007/s00125-005- 0097-z
10. H.C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan, J. Shaw, B. Zinman, and R.R. Holman Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 9541 2006 1096 1105
11. W.C. Knowler, R.F. Hamman, S.L. Edelstein, E. Barrett-Connor, D.A. Ehrmann, E.A. Walker, S.E. Fowler, D.M. Nathan, and S.E. Kahn Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program Diabetes 54 4 2005 1150 1156 doi:54/4/1150 [pii]
12. X.R. Pan, G.W. Li, Y.H. Hu, J.X. Wang, W.Y. Yang, Z.X. An, Z.X. Hu, J. Lin, J.Z. Xiao, H.B. Cao, P.A. Liu, X.G. Jiang, Y.Y. Jiang, J.P. Wang, H. Zheng, H. Zhang, P.H. Bennett, and B.V. Howard Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study Diabetes Care 20 4 1997 537 544
13. R.A. DeFronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, R.R. Henry, H.N. Hodis, A.E. Kitabchi, W.J. Mack, S. Mudaliar, R.E. Ratner, K. Williams, F.B. Stentz, N. Musi, and P.D. Reaven Pioglitazone for diabetes prevention in impaired glucose tolerance N. Engl. J. Med. 364 12 2011 1104 1115 10.1056/NEJMoa1010949
14. The Diabetes Prevention Program (DPP): Description of lifestyle intervention Diabetes Care 25 12 2002 2165 2171
15. W.C. Knowler, S.E. Fowler, R.F. Hamman, C.A. Christophi, H.J. Hoffman, A.T. Brenneman, J.O. Brown-Friday, R. Goldberg, E. Venditti, and D.M. Nathan 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 374 9702 2009 1677 1686 10.1016/S0140-6736(09)61457-4 pii:S0140-6736(09)61457-4
16. A. Briggs, and M. Sculpher An introduction to Markov modelling for economic evaluation Pharmacoeconomics 13 4 1998 397 409
17. TreeAge Software, Inc. Pro Healthcare Users Manual 2009 TreeAge Software Inc. Williamstown
18. J.B. Meigs, D.C. Muller, D.M. Nathan, D.R. Blake, and R. Andres The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging Diabetes 52 6 2003 1475 1484
19. Australian Bureau of Statistics: 2005-2007 all-cause mortality rates). Australian Government.
20. G.A. Nichols, H.S. Glauber, and J.B. Brown Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis Diabetes Care 23 11 2000 1654 1659
21. E.L.M. Barr, P.Z. Zimmet, K.R. Polkinghorne, R.C. Atkins, D.W. Dunstan, S.G. Murray, and J.E. Shaw AusDiab 2005: The Australian Diabetes, Obesity and Lifestyle Study 2006 National Health and Medical Research Council (NHMRC)
22. W.H. Herman, M. Brandle, P. Zhang, D.F. Williamson, M.J. Matulik, R.E. Ratner, J.M. Lachin, and M.M. Engelgau Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program Diabetes Care 26 1 2003 36 47
23. Medicare Benefits Schedule (MBS), May 2010, Australian Government Department of Health and Ageing, Canberra, Australia, 2010, Available from: http://www.pbs.gov.au.
24. S.C.R. Colagiuri, B. Conway, P. Davey, and D. Grainger DiabCo$t Australia. Assessing the Burden of Type 2 Diabetes in Australia December 2003 Diabetes Australia Canberra
25. American Diabetes Association Economic costs of diabetes in the U.S. in 2007 (position statement) Diabetes Care 31 2008 1 20
26. Pharmaceutical Benefits Schedule 2010 Australian Government Department of Health and Aging (accessed 16.06.2010)
27. K.S. Howard, G. White, S. Chadban, S. Craig, J. McDonald, S. Perkovic, and V.A. Cass The Cost-Effectiveness of Early Detection and Intervention to Prevent the Progression of Chronic Kidney Disease in Australia 2006 Available from http://www.kidney.org.au
28. W.H. Herman, T.J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R.F. Hamman, R.T. Ackermann, M.M. Engelgau, and R.E. Ratner The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance Ann. Intern. Med. 142 5 2005 323 332
29. M.C. Weinstein, B. O'Brien, J. Hornberger, J. Jackson, M. Johannesson, C. McCabe, and B.R. Luce Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies Value Health 6 1 2003 9 17
30. A.J. Milat, B. O'Hara, and E. Develin Concepts and new frontiers for development - what role should health promoters play in lifestyle-based diabetes prevention programs in Australia? Health Promot J Austr 20 2 2009 86 91
31. L.D. Segal, and A.J. Richardson Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Health Promot. Int. 13 1998 197 210
32. A.J. Palmer, S. Roze, W.J. Valentine, G.A. Spinas, J.E. Shaw, and P.Z. Zimmet Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom Clin. Ther. 26 2 2004 304 321
33. S. Colagiuri, and A.E. Walker Using an economic model of diabetes to evaluate prevention and care strategies in Australia Health Aff. (Millwood) 27 1 2008 256 268
34. P.M. Clarke, A.M. Gray, A. Briggs, A.J. Farmer, P. Fenn, R.J. Stevens, D.R. Matthews, I.M. Stratton, and R.R. Holman A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) Diabetologia 47 2004 1747 1759
35. S. Colagiuri, C.A. Cull, and R.R. Holman Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61 Diabetes Care 25 8 2002 1410 1417
36. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Diabetes Care 26 9 2003 2518 2523
37. D.M. Eddy, L. Schlessinger, and R. Kahn Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes Ann. Intern. Med. 143 4 2005 251 264
38. P. Wein, N. Beischer, C. Harris, and M. Permezel A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance Aust. N. Z. J. Obstet. Gynaecol. 39 2 1999 162 166
39. K. Kosaka, M. Noda, and T. Kuzuya Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males Diabetes Res. Clin. Pract. 67 2 2005 152 162 10.1016/j.diabres.2004.06.010 pii:S0168-8227(04)00178-0
40. J. Eriksson, J. Lindstrom, T. Valle, S. Aunola, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Laakso, M. Lauhkonen, P. Lehto, A. Lehtonen, A. Louheranta, M. Mannelin, V. Martikkala, M. Rastas, J. Sundvall, A. Turpeinen, T. Viljanen, M. Uusitupa, and J. Tuomilehto Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme Diabetologia 42 7 1999 793 801
41. K.F. Eriksson, and F. Lindgarde No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise Diabetologia 41 9 1998 1010 1016
42. K. Gu, C.C. Cowie, and M.I. Harris Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993 Diabetes Care 21 7 1998 1138 1145
43. S.H. Saydah, C.M. Loria, M.S. Eberhardt, and F.L. Brancati Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24 3 2001 447 453
44. A.J. Hanley, B. Zinman, P. Sheridan, S. Yusuf, and H.C. Gerstein Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial Diabetes Care 33 3 2010 608 613 doi:10.2337/dc09-1579 [pii]
45. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjostrom XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 1 2004 155 161
46. S. Coffin, C. Konduru, M. Schwarcz, and W. Frishman Surgical approaches for the prevention and treatment of type 2 diabetes mellitus Cardiol. Rev. 17 6 2009 275 279 10.1097/CRD.0b013e3181bc23d1 pii:00045415-200911000-00004
47. C.L. Keating, J.B. Dixon, M.L. Moodie, A. Peeters, L. Bulfone, D.J. Maglianno, and P.E. O'Brien Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis Diabetes Care 32 4 2009 567 574
48. J.J. Caro, D. Getsios, I. Caro, W.S. Klittich, and J.A. O'Brien Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada Diabetes Med. 21 11 2004 1229 1236
49. E.L.M. Barr, D.J. Magliano, K.R. Polkinghorne, R.C. Atkins, D.W. Dunstan, S.G. Murray, and J.E. Shaw AusDiab 2005: The Australian Diabetes, Obesity and Lifestyle Study 2006 National Health and Medical Research Council (NHMRC)